On Friday, December 9, experts highlighted the updates from SABCS 2022 that may have an immediate impact for patients and physicians.

Andrei Goga, MD, PhD; Shom Goel, MBBS; Marleen Kok, MD, PhD; and Melinda Telli, MD, outlined updates across the spectrum of breast cancer research and clinical practice on Saturday, December 10.

Viviana Galimberti, MD, and fellow panelists explored evolving questions around the utility of targeted axillary dissection, the optimal duration of endocrine therapy, and the role of neoadjuvant therapy in triple negative breast cancer during a session Wednesday, December 7.

Hope S. Rugo, MD, opened a discussion session on Thursday, December 8, which explored different opinions on the future of minimum tolerable dose (MTD), randomized trials vs. real-world evidence, and the utility of Ki67 as a clinical biomarker.

Charles M. Perou, PhD, spoke Wednesday, December 7, about the importance of quantitative and objective means for measuring the intrinsic subtypes and immune signatures of breast cancer.